Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/29549

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

COMBINED EFFECT OF CYP2B6 AND NAT2 GENOTYPE ON PLASMA EFAVIRENZ EXPOSURE DURING RIFAMPIN-BASED ANTITUBERCULOSIS THERAPY IN THE STRIDE STUDY
Luetkemeyer, Anne F. et al. | Date Issued: 2015
Author
Luetkemeyer, Anne F.
Rosenkranz, Susan L.
Lu, Darlene
Grinsztejn, Beatriz
Sanchez, Jorge
Ssemmanda, Michael
Sanne, Ian
McIlleron, Helen
Havlir, Diane V.
Haas, David W.
Affilliation
University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
IMPACTA. Lima, Peru.
Joint Clinical Research Center. Kampala, Uganda.
University of the Witwatersrand. Faculty of Health Sciences. Johannesburg, South Africa.
University of Cape Town. Department of Medicine. Division of Clinical Pharmacology Cape Town, South Africa.
University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA.
Vanderbilt University School of Medicine. Department of Medicine. Nashville, Tennessee, USA.
Abstract
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
Keywords
HIV/AIDS
Efavirenz
Pharmacogenetic
Rifampin
Tuberculosis
 
Publisher
Oxford
Citation
LUETKEMEYER, Anne F. et al. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-Based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases, v. 60, n. 12, p. 1860-1863, Jun. 2015.
DOI
10.1093/cid/civ155
ISSN
1058-4838
Notes
Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams.